title: [Clinical and pathologic analysis of 33 cases of uterine papillary serous carcinoma].
abstract: OBJECTIVE
  To analyze the clinico-pathological characteristics, prognostic factors and the rational therapy for the uterine papillary serous carcinoma (UPSC).
  
  
  METHODS
  Thirty-three cases of UPSC were treated in our hospital between January 1996 and December 2005. The clinico-pathologic characteristics, treatment and prognosis were retrospectively analyzed.
  
  
  RESULTS
  The three-year overall survival for patients with stage I, III and IV was 77.4%, 53.3% and 12.1%, respectively. Patients with late stages and deep myometrial invasion were associated with a worse prognosis by univariate analysis (P < 0.05), while in a multivariate analysis only late stages and poor differentiation were associated with a poor prognosis (P < 0.05). The prognosis of patients in late stages treated with postoperative chemotherapy was significantly better than those without chemotherapy (P = 0.014).
  
  
  CONCLUSIONS
  Most UPSC patients are in late stages at diagnosis. They often have extra-uterine metastasis and have a poor prognosis. Complete surgical staging is recommended, and postoperative chemotherapy seems to improve the prognosis.
authors.affiliation: Department of Gynecologic Oncology, Tumor Hospital, Fudan University, Shanghai 200032, China.
authors.forename: Yu-Lan
authors.initials: YL
authors.lastname: Ren
authors.forename: Hua-Ying
authors.initials: HY
authors.lastname: Wang
authors.forename: Lei
authors.initials: L
authors.lastname: Shen
authors.forename: Wen-Tao
authors.initials: WT
authors.lastname: Yang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002291:Carcinoma, Papillary / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D016889:Endometrial Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D015999:Multivariate Analysis; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D012189:Retrospective Studies; D015996:Survival Rate; D014594:Uterine Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*
chemical_list: D015251:Epirubicin; D002945:Cisplatin